Investors Face November Deadline in Unicycive Securities Lawsuit

The litigation claims that Unicycive failed to inspect or audit its third-party manufacturing vendor, leaving the firm without a reasonable basis to claim that FDA-cited deficiencies had been resolved. According to the complaint, these omissions created an undisclosed risk that regulatory approval for the drug oxylanthanum carbonate would face significant delays. Investors allege that the company’s public statements during the class period were materially misleading, ultimately resulting in financial damages when the reality of the manufacturing oversight surfaced.

Those who held shares during this window are not currently represented by counsel unless they choose to retain an attorney or are appointed as a lead plaintiff. While the case is pending, investors may opt to remain absent class members or seek independent legal guidance. Rosen Law Firm is offering representation on a contingency fee basis, meaning participants do not pay out-of-pocket costs for the legal proceedings.